Cargando…

Insulin activates EGFR by stimulating its interaction with IGF-1R in low-EGFR-expressing TNBC cells

The expression of epidermal growth factor receptor (EGFR) is an important diagnostic marker for triple-negative breast cancer (TNBC) cells, which lack three hormonal receptors: estrogen and progesterone receptors as well as epidermal growth factor receptor 2. EGFR transactivation can cause drug resi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shin, Miyoung, Yang, Eun Gyeong, Song, Hyun Kyu, Jeon, Hyesung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society for Biochemistry and Molecular Biology 2015
Materias:	Research-Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4578621/ https://www.ncbi.nlm.nih.gov/pubmed/25341922 http://dx.doi.org/10.5483/BMBRep.2015.48.6.157

Ejemplares similares

EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC
por: Liu, Yan, et al.
Publicado: (2019)

TNBC Therapeutics Based on Combination of Fusarochromanone with EGFR Inhibitors
por: Carroll, Natalie, et al.
Publicado: (2022)

BCAP31 drives TNBC development by modulating ligand-independent EGFR trafficking and spontaneous EGFR phosphorylation
por: Fu, Wenyan, et al.
Publicado: (2019)

Suppression of TNBC metastasis by doxazosin, a novel dual inhibitor of c-MET/EGFR
por: Kim, Seongjae, et al.
Publicado: (2023)

Durable Response of Spinal Chordoma to Combined Inhibition of IGF-1R and EGFR
por: Aleksic, Tamara, et al.
Publicado: (2016)

IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells
por: Merrouche, Yacine, et al.
Publicado: (2016)

Co-inhibition of EGFR and IGF1R synergistically impacts therapeutically on adrenocortical carcinoma
por: Xu, Lieyu, et al.
Publicado: (2016)

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and IGF-1R
por: Hempel, Cornelius, et al.
Publicado: (2017)

Acquisition of EGFR TKI resistance and EMT phenotype is linked with activation of IGF1R/NF-κB pathway in EGFR-mutant NSCLC
por: Li, Ling, et al.
Publicado: (2017)

Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway
por: Pan, Yong-hong, et al.
Publicado: (2018)

Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer
por: Wang, Rong, et al.
Publicado: (2020)

Insulin-like Growth Factor Binding Protein 3 Increases Mouse Preimplantation Embryo Cleavage Rate by Activation of IGF1R and EGFR Independent of IGF1 Signalling
por: Green, Charmaine J., et al.
Publicado: (2022)

Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors
por: Choi, Yun Jung, et al.
Publicado: (2013)

The impact of MET, IGF-1, IGF1R expression and EGFR mutations on survival of patients with non-small-cell lung cancer
por: Al-Saad, Samer, et al.
Publicado: (2017)

IGF-1/IGF-1R/FAK/YAP Transduction Signaling Prompts Growth Effects in Triple-Negative Breast Cancer (TNBC) Cells
por: Rigiracciolo, Damiano Cosimo, et al.
Publicado: (2020)

Correction: Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors
por: Choi, Yun Jung, et al.
Publicado: (2019)

Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFR(WT), EGFR(T790M), and EGFR(L858R))
por: Abo Al-Hamd, Mahmoud G., et al.
Publicado: (2023)

Epidermal growth factor receptor (EGFR) gene alteration and protein overexpression in Malaysian triple-negative breast cancer (TNBC) cohort
por: Zakaria, Zubaidah, et al.
Publicado: (2019)

Identifying potential ligand molecules EGFR mediated TNBC targeting the kinase domain-identification of customized drugs through in silico methods
por: Vyshnavi, Hima, et al.
Publicado: (2023)

Novel role of cannabinoid receptor 2 in inhibiting EGF/EGFR and IGF-I/IGF-IR pathways in breast cancer
por: Elbaz, Mohamad, et al.
Publicado: (2016)

Prognostic importance of PTEN, EGFR, HER-2, and IGF-1R in gastric cancer patients treated with postoperative chemoradiation
por: BENLİ YAVUZ, Berrin, et al.
Publicado: (2019)

Dual Inhibition of EGFR and IGF-1R Signaling Leads to Enhanced Antitumor Efficacy against Esophageal Squamous Cancer
por: Kang, Jia, et al.
Publicado: (2022)

miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway
por: HAN, JING, et al.
Publicado: (2016)

BIX01294 inhibits EGFR signaling in EGFR-mutant lung adenocarcinoma cells through a BCKDHA-mediated reduction in the EGFR level
por: Kim, Ji Hye, et al.
Publicado: (2021)

Interaction of EGFR to δ-catenin leads to δ-catenin phosphorylation and enhances EGFR signaling
por: He, Yongfeng, et al.
Publicado: (2016)

A case of concomitant EGFR/ALK alteration against a mutated EGFR background in early-stage lung adenocarcinoma
por: Lee, Ki-Chang, et al.
Publicado: (2021)

ALCAM-EGFR interaction regulates myelomagenesis
por: Luo, Hongmei, et al.
Publicado: (2021)

Betacellulin promotes tumor development and EGFR mutant lung cancer growth by stimulating the EGFR pathway and suppressing apoptosis
por: Chava, Suresh, et al.
Publicado: (2022)

Membranous Insulin-like Growth Factor-1 Receptor (IGF1R) Expression Is Predictive of Poor Prognosis in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma
por: Park, Eunhyang, et al.
Publicado: (2015)

Inhibition of Both EGFR and IGF1R Sensitized Prostate Cancer Cells to Radiation by Synergistic Suppression of DNA Homologous Recombination Repair
por: Wang, Yong, et al.
Publicado: (2013)

Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer
por: Zhou, Juan, et al.
Publicado: (2015)

IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations
por: Vazquez-Martin, Alejandro, et al.
Publicado: (2013)

Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer
por: Park, Silvia, et al.
Publicado: (2015)

Predictive Efficacy of Low Burden EGFR Mutation Detected by Next-Generation Sequencing on Response to EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Carcinoma
por: Kim, Hye Sook, et al.
Publicado: (2013)

EGFR Polymorphism as a Predictor of Clinical Outcome in Advanced Lung Cancer Patients Treated with EGFR-TKI
por: Jung, Minkyu, et al.
Publicado: (2012)

Systematic Identification of Oncogenic EGFR Interaction Partners
por: Petschnigg, Julia, et al.
Publicado: (2017)

Brk/PTK6 Sustains Activated EGFR Signaling through Inhibiting EGFR Degradation and Transactivating EGFR
por: Li, X, et al.
Publicado: (2012)

Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth
por: Yao, Nan, et al.
Publicado: (2020)

IGF-I, IGF-II, and Insulin Stimulate Different Gene Expression Responses through Binding to the IGF-I Receptor
por: Versteyhe, Soetkin, et al.
Publicado: (2013)

Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit
por: Raju, Uma, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_7riikeqmgegfe5095q10qljdeg